Press Release

The Global Hematology Analyzers and Reagents Market size was valued at USD 8.2 billion in 2021 and is expected to grow by USD 13.87 billion in 2030 at a CAGR of 7.6 % during the forecast period.  

The growing number of blood donation camps around the world is a major element driving demand in the hematology analyzers and reagents market. The industry is also growing due to the rising incidence of chronic disorders. The market's demand is also being accelerated by the expanding geriatric population. The rising popularity of point-of-care testing equipment is paving the way for the market to expand. The government's increasing investment assistance is having a substantial impact on the hematological market's growth. The public's enthusiasm in low-cost diagnostic methods is propelling the sector forward.  

Hematology indicators are becoming increasingly important in the assessment of COVID-19 all over the world. Several studies are being conducted in research institutions, and many hospitals have begun to use haematology analyzers to screen and monitor COVID-19 patients in order to prevent the virus from spreading. Furthermore, according to a study published in Physiological Review-Journal, high rates of enzyme loss of blood clot prevention could be a common risk factor for COVID-19. Furthermore, given the pandemic's rapid spread and limited literature, the proper treatment and management of Coronavirus (COVID-19) infection in patients with hematological problems may be difficult.   

Blood diseases have become a global health issue with a variety of causes and are linked to a high mortality rate. Anemia, blood cancer, hemorrhagic illnesses, and blood infections afflict a large number of people each year, and they affect people of all ages. According to the WHO, sickle cell trait affects one in every 12 African Americans, and inadequate hemoglobin affects 75 percent of infants worldwide. Africa accounts for more than 70% of all sickle-cell births. According to the World Health Organization, anaemia affects 47 percent of children and 13 percent of men worldwide, and it is on the rise. Anemia affects 29 percent of reproductive-age women and 38 percent of pregnant women globally, according to the National Institute of Health (NIH).

North America is expected to dominate the worldwide haematology analyzer and reagents market owing to the strong presence of key companies and rising investment to create novel and more correct result-generating medical equipment. Due to an increase in the number of diagnostic clinics and increased awareness of hematological illnesses, Europe is expected to take the lead in the worldwide haematology analyzers and reagents market. Because of the rising frequency of hematological illnesses among the patient population, the worldwide market opportunity is expected to be greatest in the undeveloped areas of Asia Pacific.   

KEY INDUSTRY DEVELOPMENTS:    

In November 2018, The US Food and Drug Administration granted PixCell Medical Technologies Ltd. 510(k) approval for its HemoScreen hematological analyzer for point-of-care use.

In March 2018, Roche's cobas m 511 hematological analyzer was cleared by the US FDA.

In May 2019, The FDA announced a Class 1 device recall for Beckman Coulter's DxH 800, DxH 600, and DxH 900 haematology analyzers due to erroneous results.

Read More Details On This Report: https://extrapolate.com/Healthcare-Medical-Devices-Biotechnology/hematology-analyzers-reagents-market/25785